Related Experiment Video

Updated: May 24, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines

Vildan B Cetintas1, Ali S Kucukaslan, Buket Kosova

  • 1Department of Medical Biology, Ege University Faculty of Medicine, Ege University School of Medicine, Bornova, Izmir, Turkey. vildan.bozok.cetintas@ege.edu.tr

Cell Biology International
|March 9, 2012
PubMed

Insights

Investigating cisplatin resistance in non-small-cell lung cancer (NSCLC) revealed decreased gene expression of key apoptosis regulators. Altered BAD protein phosphorylation also contributes to resistance, particularly in the CR-Calu1 cell line.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Cisplatin resistance is a major challenge in non-small-cell lung cancer (NSCLC) treatment.
  • Defective apoptosis pathways are implicated in the development of drug resistance.
  • Understanding these defects is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate specific defects in apoptosis contributing to cisplatin resistance in NSCLC.
  • To analyze gene expression profiles and protein phosphorylation in cisplatin-resistant NSCLC cell lines.
  • To elucidate the role of the BAD protein in acquired cisplatin resistance.

Main Methods:

  • Generation of cisplatin-resistant A549 and Calu1 NSCLC cell lines.
  • Analysis of gene expression profiles for apoptosis-related genes.
  • Determination of BAD protein phosphorylation status.
  • Assessment of cell death, cytochrome c release, and DNA fragmentation.

Main Results:

  • Resistant NSCLC cell lines exhibited decreased gene expression of BAD, Bid, caspase-4, and caspase-6.
  • Differential phosphorylation of BAD was observed, suggesting its involvement in cisplatin resistance.
  • The novel CR-Calu1 cell line showed significantly reduced DNA fragmentation, apoptotic cell ratio, and cytochrome c levels.

Conclusions:

  • Defective apoptosis, characterized by reduced gene expression of key apoptotic factors and altered BAD phosphorylation, contributes to cisplatin resistance in NSCLC.
  • The CR-Calu1 cell line serves as a valuable model for studying cisplatin resistance mechanisms.
  • Targeting apoptosis pathways may offer strategies to overcome cisplatin resistance in NSCLC.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...